A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2019
Price : $35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 28 Jan 2018 Status changed from active, no longer recruiting to completed.
- 28 Aug 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
- 28 Aug 2017 Status changed from suspended to active, no longer recruiting.